Maker of Reyataz and Sustiva Announces Enhancements to Co-Pay Benefit Program
January 21, 2010
In response to the dire financial climate in the U.S., several HIV/AIDS drug makers have created or expanded their payment assistance programs. Bristol-Myers Squibb Company (BMS), the maker of Reyataz (atazanavir) and Sustiva (efavirenz, Stocrin), is one of those companies: It launched a co-pay benefit program in April 2009, and then announced adjustments to that program last month. The changes appear to remove a $50 deductible that had been in the original program, while maintaining a $200 monthly cap on co-pay assistance.
You can read BMS' Dec. 17, 2009, announcement below.
You can find even more information on this topic in TheBody.com's collection of resources on paying for your HIV meds.
Bristol-Myers Squibb Co-Pay Program Announcement
From Bristol-Myers Squibb Company
We are enhancing our Bristol-Myers Squibb Co-pay Benefit Program beginning on January 1, 2010, for eligible new and existing REYATAZ® (atazanavir sulfate) and SUSTIVA® (efavirenz) patients who have out-of-pocket costs through their commercial insurance coverage. We recognize that, especially in this economic environment, out-of-pocket costs for HIV medicines may be prohibitive even for patients who have prescription drug benefits. This program reflects Bristol-Myers Squibb's ongoing commitment to helping patients who need our medicines to access them.
The REYATAZ and SUSTIVA Co-pay Benefit Program will allow eligible patients to save up to $200 of co-pay costs monthly, for up to a year. Bristol-Myers Squibb will now cover the first $200 of a patient's monthly co-pay or co-insurance costs; the patient will be responsible for any amount over $200.
To access this benefit, eligible patients need to obtain a Co-pay Benefit Card to take to the pharmacy each time they fill their prescription for REYATAZ or SUSTIVA. Benefit cards are available through their healthcare provider, select pharmacies, or online at www.BMSHIVCoPayProgram.com. Eligible patients who are currently utilizing our Co-pay Benefit Program for REYATAZ or SUSTIVA do not need to obtain new benefit cards. These patients will begin receiving these new benefits, subject to the new program end date, upon their next use of their Co-pay Benefit Card.
The Co-pay Benefit Card is not valid in Massachusetts or for prescriptions purchased under Medicaid, Medicare, or federal or state programs (including state prescription drug programs, or private indemnity or HMO insurance plans, which reimburse patients for the entire cost of the prescription drugs). First use must take place by December 31, 2010.
This Co-pay Benefit Program is for eligible commercially insured patients only. For patients living with HIV who are uninsured or underinsured, Bristol-Myers Squibb offers other programs to support access to medicines. Bristol-Myers Squibb provides our medicines free of charge to those who qualify through our Access Virology Patient Assistance Program and also participates in the pharmaceutical industry's Together Rx Access® Program.
This Co-pay Benefit Program is void where prohibited by law, taxed or restricted.
This article was provided by TheBody.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)